Please remember BLINCYTO may cause:

1. Neurological events, including immune effector cell-associated neurotoxicity syndrome (ICANS). Signs and symptoms of this side effect may include:
   - » Uncontrolled shaking (tremor)
   - » Confusion
   - » Disturbances of brain function (encephalopathy)
   - » Difficulty in communicating (aphasia) and/or writing (dysgraphia)
   - » Seizure (convulsion)
   - » Feeling less alert
2. Cytokine release syndrome including:
   - » Fever
   - » Chills
   - » Swelling
   - » Dizziness or lightheadedness

Please seek urgent attention from your doctor or nurse immediately or seek emergency help if you experience any of these symptoms

Please travel home safely and do not drive or operate moving vehicles/heavy machinery, or engage in hazardous activities whilst receiving BLINCYTO

Version 4.0 Approved April 2026

This Patient Card fulfills the conditions of the marketing authorization and has been approved by the competent authority

Patient Card

Please show this card to all emergency and healthcare providers

Information about BLINCYTO®▼(blinatumomab)

My name is _____

_____

In Case of Emergency (ICE) contact

_____

_____

_____

_____

I am being treated with BLINCYTO, a treatment for B-precursor acute lymphoblastic leukaemia, which can lower my immune system.

I started treatment on _____

Before providing any treatment, please call my prescribing physician at the number below. If any medical evaluations are undertaken, please provide copies of all medical records, including any treatments and/or test results, to the doctor(s) named below.

	Name	Hospital	City	Phone Number
Haematologist				
Oncologist				
Haematology Nurse				

▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this card. Side effects can be reported directly to the Health Products Regulatory Authority (HPRA) using the available methods via www.hpra.ie By reporting side effects you can help provide more information on the safety of this medicine. Side effects should also be reported to Amgen Limited on +44 (0) 1223 436441 or Freephone 1800 535 160.

Version 4.0 Approved April 2026